WO2006120696A2 - An improved pharmaceutical composition - Google Patents
An improved pharmaceutical composition Download PDFInfo
- Publication number
- WO2006120696A2 WO2006120696A2 PCT/IN2006/000054 IN2006000054W WO2006120696A2 WO 2006120696 A2 WO2006120696 A2 WO 2006120696A2 IN 2006000054 W IN2006000054 W IN 2006000054W WO 2006120696 A2 WO2006120696 A2 WO 2006120696A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- improved pharmaceutical
- composition
- aminoquinoline
- chloroquine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a pharmaceutical composition containing 4- aminoquinoline compounds and Magnesium chloride.
- the present invention also relates to the composition resulting from the said process and treatment of ocular inflammation with the said composition.
- the said ocular inflammation may also present as dry eye or ocular surface disorder.
- Inflammation of the eye may be localized to the eye, the eyes, or may be part of more generalized inflammatory process. Its etiology may be infection, allergy, immunological reactions, or as a response to surgery, injury, or due to any other causes.
- the ocular inflammation causes pain, irritation, watering, threatens visual function of the eye and may also change optical properties of the eye. Inflammation may be seen as Uveitis or keratoconjunctivitis. Inflammation may also be seen as "dry eye” or as ocular surface disorder.
- ophthalmic pharmaceutical compositions which safely and effectively treat or prevent ocular inflammation conditions.
- the anti-inflammatory properties of the anti-malarial 4-aminoquinolone pharmaceuticals are well known. They have not been used to treat inflammation of the eye because their systemic use in high closes has been associated with a rare, but serious, incidence of ocular toxicity including corneal deposits known as verticillata, loss of foveal reflex, impairment of accommodation, maculopathy and retinopathy. These effects may be reversible or irreversible.
- the present invention specifically avoids these dreaded side effects of 4 aminoquinolines by using a predetermined concentration in the composition, and by combining it with another predetermined and low concentration of magnesium chloride to achieve beneficial effects and at the same time avoid side effects.
- Magnesium chloride is a well-known electrolyte solution. It is used to wash eyes during eye surgery, along with other electrolytes.
- This 4 amino-quinolinic derivative is chloroquine and/or hydroxychloroquine and the drug can be orally administered once or several times a day.
- the ophthalmic preparation contains a tetracycline compound in aqueous solution.
- the preparation preferably further includes a balance of electrolytes sufficient to maintain or restore essentially normal levels of conjunctival mucus-containing goblet cells and corneal glycogen.
- electrolytes can include potassium, chloride, bicarbonate, sodium, calcium, magnesium and phosphate.
- Ophthalmic composition for use in ocular surgery includes an aqueous solution of sodium hyaluronate with a concentration within the range of 18-40 mg sodium hyaluronate/ml solution and the molecular mass of sodium hyaluronate being in the range of 1x106-10x106r,M.
- the composition is introduced into the eye as a surgical aid.
- the composition may be used in a method for conducting cataract surgery.
- the 4-amino-ch!oroquinoline products are useful as pharmaceuticals.
- Novel aminoquinoline derivatives of the general formula ##STR1## are described. Also described are methods for the treatment of malaria paihcger.c, particularly chlor ⁇ quine-resistance malaria pathogens with compounds of formula I or the pharmaceutically acceptable salts and hydr ⁇ !yzab!e ectere therccf. To the extent these applications and patents disclose 4-amin ⁇ qui ⁇ oline compounds and their derivatives, which are useful in the practice of the present invention, they are incorporated herein by reference.
- the 4-aminoquinoline compounds in the ophthalmic pharmaceutical composition are mefloquine, quinacrine, and cletoquine.
- a novel pharmaceutical composition for external application in inflammatory disorder of eye as eye drops, eye ointments or directly subconjunctivally or directly intra vitrea Hy is described.
- This new composition results in a prolonged and sustained intraocular levels of the active drug in mammals using formulations that not necessarily increase drug plasma levels, and therefore avoid hazards associated with raised plasma levels and implications thereof, like drug toxicity.
- Another object of the present invention is to provide prolonged stable intraocular levels of 4- aminoquinolines.
- the objects of the present invention are met and the problems and shortcomings associated with the prior art are overcome by the incorporation of the 4- aminoquinlines and magnesium chloride into a composition to be administered topically, directly to the eye, as eye drops, eye ointments, gels, a spray via an adsorbent contact lens, via a sustained release container placed in the eye, or subconjunctivally or intravitreally by direct injection.
- Compounds suitable for the composition of the present invention herein include chloroquine, amodiaquine, an isomer, or a salt thereof, and structurally ⁇ irr. ⁇ sr compounds and magnesium chloride, or a salt thereof, and structurally similar compounds.
- salt thereof is meant to include any nontoxic pharmaceutically suitable salt of a compound described hereinabove with the desired pharmacological properties in mammals. Preparation of such a salt is well known to those skilled in pharmaceutical science.
- 4-aminoquinoline and magnesium chloride compounds are non-toxic to the eye when administered directly to the eye. Ocular administration permits the compound to be administered in adequate ocular doses and to maintain intraocular levels of the compound for prolonged periods.
- the 4-aminoquinolone compounds and magnesium chloride when used in ophthalmic pharmaceutical composition are effective in preventing and treating ocular inflammation of varied etiology such as immune disease factors, surgery, chemical or mechanical injury, injury due to exposure to radiation, infrared or ultraviolet rays, degenerative changes, allergic conjunctivitis, allergic responses in the eye.
- the present invention i.e. the pharmaceutical substance obtained by the process as herein described is a totally different and novel pharmaceutical composition, having synergetic properties.
- the ophthalmic pharmaceutical compositions of this invention contain one or more 4 «aminoquinoline and magnesium chloride compounds as the active component(s).
- the following terms will first be defined.
- “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts which are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetra-alkyl-ammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, hydroiodide, tartrate, and the like.
- the base salts for example, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or alkyl ammonium salts.
- Solution one (1) contained chloroquine phosphate aqueous solution 0.03 gm%
- Solution two (2) contained aqueous solution magnesium chloride 0.0003 gm%
- Solution three (3) contained aqueous solution chloroquine phosphate 0.03gm% and magnesium chloride 0.003gm%
- Solution four (4) contained plain sodium chloride 0.9gms% as control.
- Fresh ocular ectodermal cells attached to the basement membrane were taken on four glass slides.
- the cells on slide number 1 were treated with solution 1.
- the slides were exposed to UV light, which peaked at wavelength of 390 nanometers, by placing them equidistantly from the source so that all the cells on the slides got equal exposure.
- the exposure time was 10 seconds.
- the slides were stained with Leishmann stain and examined under microscope.
- the cells were observed for signs of damage due to the Ultraviolet light.
- Irregular shape in more than 50% cells - 4 points Irregular shape in 80% cells - 3 points
- Solution 2 3 points
- Solution s 15 points
- a novel pharmaceutical composition for external application in inflammatory disorders of eye comprising reacting 4-aminoquinolines and magnesium chloride with water, and ophthalmically acceptable acids and bases to adjust the pH, tonicity imparting agents, antimicrobial preservatives, suitable absorption enhancers, and stabilizing agents, bases for ointments for treatment of inflammatory disorders.
- Said 4 aminoquinolines is with concentrations between 0.001 nanograms per ml. and 1.00 mg per ml and magnesium chloride between 0.0001 grams percent to
- composition which forms a novel Pharmaceutical compound when 4 aminoquinoline is mixed with magnesium chloride along with water.
- the 4 aminoquinoline is chloroquine or its derivatives, isomers, salts.
- the said 4 aminoquinoline is hydroxychloroquine sulphate, chloroquine phosphate, chloroquine phosphate is amodiaquine or its derivatives, isomers, salts.
- the said 4 aminoquinoline compound is selected from the group comprising of Chloroquine phosphate,
- Tonicity-imparting agents such as sorbitol, glycerin and dextrose are added.
- antimicrobial preservatives such as parahydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, benzalkonium chloride are added.
- suitable absorption enhancers such as surfactants, bile acids are added.
- stabilizing agents such as antioxidants like bisulfites and ascorbates are added.
- viscosity- imparting agents such as sodium carboxymethyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and polyvinyl alcohol are added.
- said wetting agent is carboxymethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, or hydroxyethylcellulose, or artificial tears.
- ophthalmically acceptable acids and bases are employed to adjust the pH, tonicity imparting agents, antimicrobial preservatives, suitable absorption enhancers, and stabilizing agents, bases for ointments prevents protein unfolding that results due to a heat shock.
- the said compound is formulated as a suspension, solution, salve, ointment, spray, liposomal composition, nonoemulsion particle composition, or chitosan particle composition, slow release inserts, via contact lens.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical composition containing 4-aminoquinoline compounds and Magnesium chloride for treatment of ocular inflammation of varied etiology such as immune disease factors, surgery, chemical or mechanical injury or prevention of injury due to exposure to radiation, infra-red or ultra-violet rays, degenerative changes, allergic or infective etiology using the novel pharmaceutical composition of the present invention.
Description
AN IMPROVED PHARMACEUTICAL COMPOSITION
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition containing 4- aminoquinoline compounds and Magnesium chloride.
The present invention also relates to a treatment of ocular inflammation of varied etiology such as immune disease factors, surgery, chemical or mechanical injury or prevention of injury due to exposure to radiation, infra-red or ultra-violet rays, degenerative changes, allergic or infective etiology using the novel pharmaceutical composition of the present invention.
The present invention also relates to the composition resulting from the said process and treatment of ocular inflammation with the said composition. The said ocular inflammation may also present as dry eye or ocular surface disorder.
BACKGROUND OF THE INVENTION
Inflammation of the eye may be localized to the eye, the eyes, or may be part of more generalized inflammatory process. Its etiology may be infection, allergy, immunological reactions, or as a response to surgery, injury, or due to any other causes. The ocular inflammation causes pain, irritation, watering, threatens visual function of the eye and may also change optical properties of the eye. Inflammation may be seen as Uveitis or keratoconjunctivitis. Inflammation may also be seen as "dry eye" or as ocular surface disorder.
Accordingly, a need exists for novel ophthalmic pharmaceutical compositions, which safely and effectively treat or prevent ocular inflammation conditions.
The anti-inflammatory properties of the anti-malarial 4-aminoquinolone pharmaceuticals are well known. They have not been used to treat inflammation of the eye because their systemic use in high closes has been associated with a rare, but serious, incidence of ocular toxicity including corneal deposits known as verticillata, loss of foveal reflex, impairment of accommodation, maculopathy and retinopathy. These effects may be reversible or irreversible.
The present invention specifically avoids these dreaded side effects of 4 aminoquinolines by using a predetermined concentration in the composition, and by combining it with another predetermined and low concentration of magnesium chloride to achieve beneficial effects and at the same time avoid side effects.
The 4-aminoquinoline compounds used in prior art in ophthalmic pharmaceutical compositions have been previously reported to be useful as therapeutics in the treatment of malaria and rheumatoid arthritis.
In yet another prior art it was disclosed that 4-aminoquinolines have strong antiinflammatory action and are very effective for inflammatory diseases. Rynes, Rl, 36 BR J RHEUMATOL 799-805 (1997).
Magnesium chloride is a well-known electrolyte solution. It is used to wash eyes during eye surgery, along with other electrolytes.
It has now been found that certain 4-aminoquinolone compounds along with magnesium chloride are useful for preventing and treating ocular inflammation by application of the compositions to the eye prior to, during and after an inflammatory disorder, especially inflammation of the outer and middle coats of the eye, such as dry eye, etc.
PRIORART
4-aminoquinolines and their derivatives to be used in present invention and processes for preparing these compositions are disclosed in: U.S. Patent No.4,421,920 to Baudouin, U.S. Patent No. 5,596,002, to Hofheinz, and U.S. Patent No. 5,948,791 , to Hofheinz, References:
EP Patent No. 1,374,867.
WO Patent No. 0007601
US Patent No. 6,086,597.
U.S. Patent No. 4,421,920. U.S. Patent No. 5,596,002.
U.S. Patent No. 5,948,791.
EP No.: 1, 374,867
Use of at least one 4 amino-quinolinic derivative to obtain a drug for the anti- retroviral therapy, especially in the therapy of the HIV disease-infection caused by retroviral strains, which are sensitive and/or resistant to known therapies. This 4 amino-quinolinic derivative is chloroquine and/or hydroxychloroquine and the drug can be orally administered once or several times a day.
WO patent application No.: 0007601
Ophthalmic compositions and methods of using the same to simultaneously treat eye surface inflammation and dry eye are disclosed. The ophthalmic preparation contains a tetracycline compound in aqueous solution. The preparation preferably further includes a balance of electrolytes sufficient to maintain or restore essentially normal levels of conjunctival mucus-containing goblet cells
and corneal glycogen. These electrolytes can include potassium, chloride, bicarbonate, sodium, calcium, magnesium and phosphate.
US Patent No,: 6086597
Ophthalmic composition for use in ocular surgery includes an aqueous solution of sodium hyaluronate with a concentration within the range of 18-40 mg sodium hyaluronate/ml solution and the molecular mass of sodium hyaluronate being in the range of 1x106-10x106r,M. In a method for conducting ocular surgery, the composition is introduced into the eye as a surgical aid. The composition may be used in a method for conducting cataract surgery.
U.S. Patent No.: 4,421,920
4-Amino-chloroquinolines of the formula: ##STR1## in which R.sub.1 represents a hydrogen atom or an alkyl radical (1 to 5 carbon atoms), and R.sub.2 represents an alkyl radical (1 to 5 carbon atoms) optionally substituted by a dialkylamino group, or a phenyl radical optionally substituted by one or more carboxy and hydroxy radicals and alkyi radicals (1 to 4 carbon atoms) optionally substituted by a dialkylamino group, are prepared by the condensation of an amine of the formula: ##STR2## with a chloro-1 ,2,3,4-tetrahydroquinolin-4-one of the formula: ##STR3## with aromatization of the tetrahydroquinoline, the reaction being carried out in the presence of a ruthenium based catalyst on a support. The 4-amino-ch!oroquinoline products are useful as pharmaceuticals.
U.S. Patent No.: 5,596,002
Novel aminoquinoline derivatives of the general formula ##STR1## are described. Also described are methods for the treatment of malaria paihcger.c, particularly chlorαquine-resistance malaria pathogens with compounds of formula I or the pharmaceutically acceptable salts and hydrα!yzab!e ectere therccf.
To the extent these applications and patents disclose 4-aminσquiπoline compounds and their derivatives, which are useful in the practice of the present invention, they are incorporated herein by reference.
In the preferred embodiment, the 4-aminoquinoline compounds in the ophthalmic pharmaceutical composition are mefloquine, quinacrine, and cletoquine.
A novel pharmaceutical composition for external application in inflammatory disorder of eye as eye drops, eye ointments or directly subconjunctivally or directly intra vitrea Hy is described. This new composition results in a prolonged and sustained intraocular levels of the active drug in mammals using formulations that not necessarily increase drug plasma levels, and therefore avoid hazards associated with raised plasma levels and implications thereof, like drug toxicity.
Another object of the present invention is to provide prolonged stable intraocular levels of 4- aminoquinolines.
It is also an object of the present invention to provide sustained intraocular levels of 4-aminoquinolines without having to increase their plasma levels.
The objects of the present invention are met and the problems and shortcomings associated with the prior art are overcome by the incorporation of the 4- aminoquinlines and magnesium chloride into a composition to be administered topically, directly to the eye, as eye drops, eye ointments, gels, a spray via an adsorbent contact lens, via a sustained release container placed in the eye, or subconjunctivally or intravitreally by direct injection.
Compounds suitable for the composition of the present invention herein include chloroquine, amodiaquine, an isomer, or a salt thereof, and structurally εirr.ϋsr
compounds and magnesium chloride, or a salt thereof, and structurally similar compounds.
As used above, the term "salt thereof is meant to include any nontoxic pharmaceutically suitable salt of a compound described hereinabove with the desired pharmacological properties in mammals. Preparation of such a salt is well known to those skilled in pharmaceutical science.
4-aminoquinoline and magnesium chloride compounds are non-toxic to the eye when administered directly to the eye. Ocular administration permits the compound to be administered in adequate ocular doses and to maintain intraocular levels of the compound for prolonged periods. The 4-aminoquinolone compounds and magnesium chloride when used in ophthalmic pharmaceutical composition, are effective in preventing and treating ocular inflammation of varied etiology such as immune disease factors, surgery, chemical or mechanical injury, injury due to exposure to radiation, infrared or ultraviolet rays, degenerative changes, allergic conjunctivitis, allergic responses in the eye.
Therefore, the present invention, i.e. the pharmaceutical substance obtained by the process as herein described is a totally different and novel pharmaceutical composition, having synergetic properties.
The ophthalmic pharmaceutical compositions of this invention contain one or more 4«aminoquinoline and magnesium chloride compounds as the active component(s). Prior to describing this invention in further detail, the following terms will first be defined.
"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts which are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetra-alkyl-ammonium, and the like; and when
the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, hydroiodide, tartrate, and the like. Among the conventional salts which can be utilized there are the base salts, for example, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or alkyl ammonium salts.
EXPERIMENTS CONDUCTED TO DEMONSTRATE SYNERGISTIC ACTION OF CHLOROQUINE AND MAGNESIUM CHLORIDE.
Four solutions were prepared.
Solution one (1) contained chloroquine phosphate aqueous solution 0.03 gm% Solution two (2) contained aqueous solution magnesium chloride 0.0003 gm% Solution three (3) contained aqueous solution chloroquine phosphate 0.03gm% and magnesium chloride 0.003gm%
Solution four (4) contained plain sodium chloride 0.9gms% as control.
Fresh ocular ectodermal cells attached to the basement membrane were taken on four glass slides.
The cells on slide number 1 were treated with solution 1.
Similarly, cells on slides number 2, 3 and 4 were treated with solutions 2, 3 and 4.
The slides were exposed to UV light, which peaked at wavelength of 390 nanometers, by placing them equidistantly from the source so that all the cells on the slides got equal exposure. The exposure time was 10 seconds.
The slides were stained with Leishmann stain and examined under microscope.
The cells were observed for signs of damage due to the Ultraviolet light.
The criteria that were used were Uniformity of shape. Uniform round shape 5 points
Irregular shape in more than 50% cells - 4 points
Irregular shape in 80% cells - 3 points
Creation, truncation of cell wall - 1 point.
Rupture of cell wall zero points.
Intercellular distance Uniform closely packed cells 5 points
Increase in cell distance so that half the cells were covered by a standard high power microscope field 4 points
One third cells were covered by the field 3 points
No cells- zero points. Vacuolation of nucleus
No vacuoles - 5 points
Vacuoles in 50% of cells in a field - 4 points
Vacuoles in 80% of cells in a field - 3 points
Vacuoles in ail cells - 0 points.
The scores were tabulated and analyzed.
The scores were as follows :
Solution 1 : 8 points
Solution 2: 3 points Solution s: 15 points
Solution 4: 1 point.
CONCLUSION
Therefore, the photo protective action of Chloroquine phosphate combined with magnesium chloride in the above solution is not a simple additive effect of each, but the effect is produced by a synergistic action of both.
STATEMENT OF THE INVENTION!
Therefore, according to the present invention, a novel pharmaceutical composition for external application in inflammatory disorders of eye comprising reacting 4-aminoquinolines and magnesium chloride with water, and ophthalmically acceptable acids and bases to adjust the pH, tonicity imparting agents, antimicrobial preservatives, suitable absorption enhancers, and stabilizing agents, bases for ointments for treatment of inflammatory disorders. Said 4 aminoquinolines is with concentrations between 0.001 nanograms per ml. and 1.00 mg per ml and magnesium chloride between 0.0001 grams percent to
0.3 grams percent along with water.
The said composition, which forms a novel Pharmaceutical compound when 4 aminoquinoline is mixed with magnesium chloride along with water.
The 4 aminoquinoline is chloroquine or its derivatives, isomers, salts. The said 4 aminoquinoline is hydroxychloroquine sulphate, chloroquine phosphate, chloroquine phosphate is amodiaquine or its derivatives, isomers, salts.
The said 4 aminoquinoline compound is selected from the group comprising of Chloroquine phosphate,
Hydroxychloroquine,
Chloroquine hydrochloride,
N1N Dideethyl chloroquine,
Mefloquine, Cletoquine.
In the said composition Tonicity-imparting agents such as sorbitol, glycerin and dextrose are added.
In the said composition antimicrobial preservatives such as parahydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, benzalkonium chloride are added. In the said composition suitable absorption enhancers such as surfactants, bile
acids are added. In the said composition stabilizing agents such as antioxidants like bisulfites and ascorbates are added. In the said composition viscosity- imparting agents such as sodium carboxymethyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and polyvinyl alcohol are added. In the said composition said wetting agent is carboxymethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, or hydroxyethylcellulose, or artificial tears.
In the present invention ophthalmically acceptable acids and bases are employed to adjust the pH, tonicity imparting agents, antimicrobial preservatives, suitable absorption enhancers, and stabilizing agents, bases for ointments prevents protein unfolding that results due to a heat shock.
The said compound is formulated as a suspension, solution, salve, ointment, spray, liposomal composition, nonoemulsion particle composition, or chitosan particle composition, slow release inserts, via contact lens.
Detailed descriptions of the preferred embodiment are provided herein; however, it is to be understood that the present invention may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching one skilled in the art to employ the present invention in virtually any appropriately detailed system, structure or manner.
Claims
1. An improved pharmaceutical composition comprising reacting 4- aminoquinoiines and magnesium chloride with water, ophthalmically acceptable acids and bases to adjust the pH, tonicity imparting agents, antimicrobial preservatives, suitable absorption enhancers, stabilizing agents, wetting agents and bases for treatment of inflammatory disorders.
2. An improved pharmaceutical composition as claimed in claim 1 , wherein the concentration of 4 aminoquinoiines is between 0.001 nano-grams per ml. to 1.00 mg per ml of water.
3. An improved pharmaceutical composition as claimed in claim 1 , wherein the concentration of magnesium chloride is between 0.0001 grams percent to 0.3 grams percent with water.
4. An improved pharmaceutical composition as claimed in claim 1 and 2 wherein the said 4 aminoquinoline is chloroquine or its derivatives or isomers or salts.
5. An improved pharmaceutical composition as claimed in claim 4, wherein 4 aminoquinoline is hydroxychloroquine sulphate.
6. An improved pharmaceutical composition as claimed in claim 4, wherein 4 aminoquinoline is chloroquine phosphate.
7. An improved pharmaceutical composition as claimed in claim 6, wherein 4 aminoquinoline is chloroquine phosphate or amodiaquine or its derivatives, isomers, salts.
8. An improved pharmaceutical composition as claimed in claim 1 and 4, wherein 4 aminoquinoline compound is selected from the group of Chloroquine phosphate, Hydroxychloroquine, Chloroquine hydrochloride,
N1N Dideethyl chloroquine, Mefloquine.or Cletoquine.
9. An improved pharmaceutical composition as claimed in claim 1 , wherein tonicity-imparting agents are sorbitol, glycerin, and dextrose.
10.An improved pharmaceutical composition as claimed in claim 1 , wherein antimicrobial preservatives are parahydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, benzalkonium chloride.
11.An improved pharmaceutical composition as claimed in claim 1, wherein absorption enhancers are surfactants, bile acids.
12. An improved pharmaceutical composition as claimed in claim 1 , wherein stabilizing agents are antioxidants like bisulfites and ascorbates.
13. An improved pharmaceutical composition as claimed in claim 1 , wherein viscosity-imparting agents are sodium carboxymethyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, and polyvinyl alcohol.
14. An improved pharmaceutical composition as claimed in claim 1 , wherein said wetting agent is carboxymethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, or hydroxyethylcellulose, or artificial tears.
15. An improved pharmaceutical composition as claim in claim 1 , wherein the said composition is formulated as a suspension, solution, salve, ointment, spray, liposomal composition, non-emulsion particle composition, or chitosan particle composition, slow release inserts, via contact lens.
16. A novel pharmaceutical composition as claimed in claims 1 to 15 hereinabove substantially as herein described with reference to the accompanying specification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007555780A JP4239036B2 (en) | 2005-02-21 | 2006-02-20 | Improved pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN182/MUM/2005 | 2005-02-21 | ||
IN182MU2005 | 2005-02-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006120696A2 true WO2006120696A2 (en) | 2006-11-16 |
WO2006120696A3 WO2006120696A3 (en) | 2007-01-04 |
Family
ID=37059683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2006/000054 WO2006120696A2 (en) | 2005-02-21 | 2006-02-20 | An improved pharmaceutical composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4239036B2 (en) |
WO (1) | WO2006120696A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2057983A1 (en) * | 2007-11-07 | 2009-05-13 | Bruschettini S.r.l. | Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
WO2009089401A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
WO2009089399A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101067443B1 (en) * | 2009-06-23 | 2011-09-27 | 여오영 | Local injection composition comprising hydroxychloroquine for treatment of hemorrhoids |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097025A2 (en) * | 2002-05-17 | 2003-11-27 | Rajeev Raut | A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom |
-
2006
- 2006-02-20 JP JP2007555780A patent/JP4239036B2/en not_active Expired - Fee Related
- 2006-02-20 WO PCT/IN2006/000054 patent/WO2006120696A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097025A2 (en) * | 2002-05-17 | 2003-11-27 | Rajeev Raut | A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom |
Non-Patent Citations (1)
Title |
---|
EGBE-NWIYI T N ET AL: "The effect of high oral magnesium chloride supplementation on the pathogenicity of Trypanosoma brucei brucei and T. congolense infections in rats." TROPICAL VETERINARIAN, vol. 21, no. 3, 2003, pages 152-159, XP001247134 ISSN: 0794-4845 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2057983A1 (en) * | 2007-11-07 | 2009-05-13 | Bruschettini S.r.l. | Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
WO2009059748A2 (en) * | 2007-11-07 | 2009-05-14 | Bruschettini S.R.L. | Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
WO2009059748A3 (en) * | 2007-11-07 | 2009-09-03 | Bruschettini S.R.L. | Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
WO2009089401A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
WO2009089399A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
WO2009089399A3 (en) * | 2008-01-10 | 2009-10-08 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
WO2009089401A3 (en) * | 2008-01-10 | 2010-06-24 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
Also Published As
Publication number | Publication date |
---|---|
JP4239036B2 (en) | 2009-03-18 |
JP2008530202A (en) | 2008-08-07 |
WO2006120696A3 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6333045B1 (en) | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | |
US7875271B2 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
AU742237B2 (en) | Use of 11-(3-dimenthylaminopropylidene)-6,11-dihydrodibenz (B,E)oxepin-2-acetic acid for the manufacture of medicament for treating non-allergic opthalmic inflammatory disorders and for the prevention of ocular neovascularization | |
US20060014786A1 (en) | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
ES2357801T3 (en) | THERAPEUTIC AGENT FOR QUERATOCONJUNCTIVE DISORDER. | |
KR920001461B1 (en) | Process for preparing ophthalmic solution | |
EP1558254B1 (en) | Use of 4-aminoquinolines compounds for the treatment of inflammatory disorders of the eye | |
US20090209599A1 (en) | Eye drop containing roflumilast | |
US20120004158A1 (en) | Quaternised Ammonium Cyclodextrin Compounds | |
EP0604570B1 (en) | Compositions containing quinolone antibiotics and sulfonate of polystyrol | |
WO2006120696A2 (en) | An improved pharmaceutical composition | |
EP0996442B1 (en) | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative | |
GB2042338A (en) | Composition for treating glaucoma | |
US20100203079A1 (en) | Ophthalmic composition containing xanthan gum and amino acid | |
KR20100014858A (en) | Olopatadine formulations for topical nasal administration | |
JPH11189533A (en) | Eye drop | |
US20090030001A1 (en) | Therapeutic agent for corneal disease | |
PL215012B1 (en) | New derivatives of benzo[g]quinoline, pharmaceutical compositions containing them and pharmaceutical applications of these compounds | |
JP2852607B2 (en) | Dry eye treatment | |
US11672798B2 (en) | Ciprofloxacin ophthalmic topical composition for treating ocular disease | |
WO1998053828A1 (en) | Israpafant-containing water-base preparations | |
WO2006075748A1 (en) | Therapeutic agent for allergic conjunctival disease | |
JPH07103022B2 (en) | Glaucoma treatment formulation containing trifluoromethanesulfonamide | |
Tai-Lee et al. | Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers | |
JP2006219487A (en) | Remedy for allergic conjunctival disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007555780 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06766246 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 6766246 Country of ref document: EP |